Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML Article
Full Text via DOI: 10.1182/blood-2023-178802
Web of Science: 001159306706010